This Pharma Stock Is Poised to Keep Outperforming the S&P 500

Published on 30 May 2024 on Motley Fool via Yahoo Finance

This Pharma Stock Is Poised to Keep Outperforming the S&P 500

AstraZeneca (NASDAQ: AZN), recognized as the world's sixth-largest pharmaceutical entity by market capitalization, made a bold proclamation in May 2014. The company set an ambitious goal of achieving annual revenue exceeding $45 billion by 2023.

This target was met with skepticism by Wall Street and dismissed as excessively optimistic. Contrary to these doubts, however, AstraZeneca realized this revenue milestone and surpassed the S&P 500 in total returns, including dividends, within the same time frame.

AZN Total Return Level Chart

Read the rest of the article

LSE.AZN price evolution

NASDAQ.AZN price evolution

Want to become a better investor?

Start tracking your investments with Statfolio

News

This Pharma Stock Is Poised to Keep Outperforming the S&P 500

LSE.AZN price evolution

NASDAQ.AZN price evolution

Want to become a better investor?

3 No-Brainer Stocks to Buy in June

AstraZeneca shares target raised by Argus on new drug approvals By Investing.com

This Pharma Stock Is Poised to Keep Outperforming the S&P 500

Goldman Sachs Says Buy European Pharma Stocks Touting Innovation

Amgen Secures FDA Nod For Rare-Disease Treatment Biosimilar Based On AstraZeneca's Drug

AstraZeneca (AZN) Falls on Failure to Meet NSCLC Study OS Goal

AstraZeneca Plans to Rake in $80 Billion by 2030. Should You Buy the Stock?

AstraZeneca Just Massively One-Upped Pfizer. Here's What It Means for the Stock

Why Is AstraZeneca Stock Trading Lower On Tuesday?

Why Is AstraZeneca Stock Trading Lower On Tuesday?